Control of Trabecular Meshwork Cytoskeleton
Control of Trabecular Meshwork Cytoskeleton
批准号:
8691189
负责人:
Donna M Peters
金额:
$33.32万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-15 至 2018-03-31
关键词:
ActinsAffectAfrican AmericanAnteriorAntibodiesAqueous HumorBindingBiological ProcessBlindnessCell surfaceCellsCytoplasmic TailCytoskeletonDepositionDexamethasoneEventEyeFamilyFamily suidaeGeneral PopulationGlaucomaGlucocorticoidsGoalsGrantGuanineGuanine Nucleotide Exchange FactorsImmunofluorescence MicroscopyImmunoprecipitationIntegrin Signaling PathwayIntegrinsKnock-outLabelLeadMeasurementMeasuresMediatingMolecular ConformationMovementMutationOperative Surgical ProceduresOptic NerveOrgan Culture TechniquesPathway interactionsPatientsPhagocytosisPhysiologic Intraocular PressurePlayPrimary Open Angle GlaucomaProcessProtein Binding DomainProteinsRetinal Ganglion CellsRisk FactorsRoleSignal PathwaySignal TransductionSiteSmall Interfering RNAStaphylococcus aureusSteroidsStimulusTestingTissuesTrabecular meshwork structureUveitisViral VectorWestern Blottingcaveolin 1crosslinkfilamininhibitor/antagonistoptic nerve disorderoverexpressionpaxillinpressurepreventpublic health relevancereceptorsmall hairpin RNAstable cell linetherapeutic target
中文摘要
描述(由申请人提供):该基金的长期目标是确定如何控制avb 3整合素信号传导机制,以开发治疗靶点来控制青光眼中的吞噬作用和外流功能。青光眼导致视网膜神经节细胞的不可逆损失,影响全球约6700万人。它们通常与眼内压(IOP)水平升高相关,这是由于小梁网(TM)的房水流出减少。其中一个主要的因素,已成为一个重要的调节机制流出设施是肌动蛋白细胞骨架。它控制着许多关键的生物过程,这些生物过程涉及维持正常的流出设施,包括收缩性、吞噬作用和基质沉积。整合素在调节细胞凋亡中起着核心作用。
肌动蛋白细胞骨架的活性和我们的研究表明,AVB 3整联蛋白的失调可能是青光眼期间观察到的一些变化的原因,包括吞噬作用和流出功能的降低。我们认为,这种整合素可能是慢性激活的青光眼,特别是类固醇诱导的青光眼过程中所谓的由内而外的信号。当次级刺激如地塞米松诱导细胞内蛋白质表达或结合至整联蛋白亚基的细胞质尾部时,发生由内向外信号传导。这种结合触发整联蛋白的活性构象。一旦这种整合素被激活,它将通过触发阻止吞噬作用的Rac 1/Trio通路而导致吞噬作用和流出设施的减少。我们计划通过使用活化抗体诱导avb 3整合素的活性构象或病毒载体在猪器官培养的眼前节中过表达活化的avb 3整合素来验证这一假设。然后,我们计划确定这种激活的avb 3整合素的表达是否会导致吞噬作用和流出设施的减少。我们还计划确定avb 3整联蛋白用于减少吞噬作用的Rac 1/Trio通路是否参与流出功能的减少,以及地塞米松治疗如何引起avb 3整联蛋白的激活。最后,我们计划确定类固醇治疗后流出道功能的增加是否与TM中avb 3整合素表达水平相关。这些研究应该表明b3整合素信号通路是否参与类固醇诱导的青光眼,并确定沿着通路的位点,我们可以靶向增加患病眼睛的流出功能。
英文摘要
DESCRIPTION (provided by applicant): The long-term objective of this grant is to identify how to control avb3 integrin signaling mechanisms in order to develop therapeutic targets to control phagocytosis and outflow facility in glaucoma. The glaucomas, which lead to irreversible loss of retinal ganglion cells, affect approximately 67 million people worldwide. They are commonly associated with elevated levels of intraocular pressure (IOP) due to a reduction in aqueous humor outflow from the trabecular meshwork (TM). One of the major factors that have emerged as an important regulatory mechanism for outflow facility is the actin cytoskeleton. It controls a number of key biological processes involved in maintaining normal outflow facility including contractility, phagocytosis, and matrix deposition. Integrins play a central role in regulating the
activity of actin cytoskeleton and our studies suggest that dysregulation of the avb3 integrin may be responsible for some of changes observed during glaucoma including decreased phagocytosis and outflow facility. We propose that this integrin may be chronically activated in glaucoma, especially steroid induced glaucoma during a process called inside-out signaling. Inside-out signaling occurs when a secondary stimulus such as dexamethasone induces the expression, or binding, of intracellular proteins to the cytoplasmic tails of the integrin subunits This binding triggers the active conformation of the integrin. Once this integrin is activated, it would cause a decrease in phagocytosis and outflow facility by triggering a Rac1/Trio pathway that prevents phagocytosis. We plan to test this hypothesis by using an activating antibody to induce the active conformation of avb3 integrin or viral vectors to overexpress an activated avb3 integrin in porcine organ cultured anterior segments. We then plan to determine if expression of this activated avb3 integrin causes a decrease in phagocytosis and outflow facility. We also plan to determine if the Rac1/Trio pathway utilized by avb3 integrin to decrease phagocytosis is involved in the decrease in outflow facility and how dexamethasone treatment causes the activation of the avb3 integrin. Finally, we plan to determine if increases in outflow facility following steroid treatment correlate with the levels of avb3 integrin expression in the TM. These studies should show whether b3 integrin signaling pathway(s) could be involved in steroid induced glaucoma and identify sites along the pathway that we can target to increase outflow facility in the diseased eye.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NFAT and fibrosis in the trabecular meshwork
-
批准号:10630268
-
项目类别:
-
资助金额:$41.6万
-
财政年份:2022
-
负责人:Donna M Peters
-
依托单位:
NFAT and fibrosis in the trabecular meshwork
-
批准号:10436632
-
项目类别:
-
资助金额:$42.0万
-
财政年份:2022
-
负责人:Donna M Peters
-
依托单位:
Targeting the Anterior Segment with Homing Peptides from Phage Display
-
批准号:8487758
-
项目类别:
-
资助金额:$22.58万
-
财政年份:2013
-
负责人:Donna M Peters
-
依托单位:
Targeting the Anterior Segment with Homing Peptides from Phage Display
-
批准号:8651496
-
项目类别:
-
资助金额:$18.44万
-
财政年份:2013
-
负责人:Donna M Peters
-
依托单位:
Integrin Signaling in the Trabecular Meshwork
-
批准号:8264354
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2010
-
负责人:Donna M Peters
-
依托单位:
Integrin Signaling in the Trabecular Meshwork
-
批准号:7862023
-
项目类别:
-
资助金额:$36.01万
-
财政年份:2010
-
负责人:Donna M Peters
-
依托单位:
Integrin Signaling in the Trabecular Meshwork
-
批准号:8059627
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2010
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7489937
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7141361
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:10316183
-
项目类别:
-
资助金额:$44.08万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:10557068
-
项目类别:
-
资助金额:$41.37万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7908762
-
项目类别:
-
资助金额:$35.33万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:8183518
-
项目类别:
-
资助金额:$37.63万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:9907633
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7661506
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7812209
-
项目类别:
-
资助金额:$48.45万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
Control of Trabecular Meshwork Cytoskeleton
-
批准号:7285580
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2006
-
负责人:Donna M Peters
-
依托单位:
CORE--PATHOLOGY/IMAGING
-
批准号:6949286
-
项目类别:
-
资助金额:$17.57万
-
财政年份:2005
-
负责人:Donna M Peters
-
依托单位:
UW Vision Research Core 2 - Pathology and Imaging
-
批准号:10273753
-
项目类别:
-
资助金额:$17.83万
-
财政年份:2005
-
负责人:Donna M Peters
-
依托单位:
Core Grant for Vision Research Core 2
-
批准号:10715683
-
项目类别:
-
资助金额:$26.64万
-
财政年份:2005
-
负责人:Donna M Peters
-
依托单位:
海外基金